A comparison of the anti-arrhythmic actions of I.C.I. 50172 and (--)-propranolol and their effects on intracellular cardiac action potentials and other features of cardiac function

British Journal of Pharmacology
J G Papp, E M Williams


1. I.C.I. 50172 had marked quinidine-like effects on intracellular cardiac action potentials at concentrations above 20 mg/l. (6.61 x 10(-5)M). The rate of rise and overshoot of the action potential, conduction velocity and contractions were decreased. (-)-Propranolol had similar effects at less than 1/30 this concentration.2. I.C.I. 50172 had 1/100 the activity of (-)-propranolol as a local anaesthetic. Since this is also the ratio of their in vitro beta-receptor blocking activities, I.C.I. 50172 provides no net increase in specificity of beta-receptor blockade.3. In contrast, the in vivo activity of I.C.I. 50172 in protecting anaesthetized guinea-pigs against ouabain-induced ventricular fibrillation was 40% that of (-)-propranolol.4. Structure-activity relations of beta-receptor blocking drugs are discussed.


Jan 1, 1968·Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie·A M BarrettL H Smith
Jan 1, 1966·British Journal of Pharmacology and Chemotherapy·B G Benfey, D R Varma
Feb 10, 1967·Annals of the New York Academy of Sciences·J R Blinks
Jan 1, 1968·British Journal of Pharmacology and Chemotherapy·D Dunlop, R G Shanks
Jul 20, 1968·British Medical Journal·D G GibsonE Sowton
Feb 1, 1969·British Journal of Anaesthesia·M Johnstone
Jun 1, 1969·British Journal of Pharmacology·A N DohadwallaE M Vaughan Williams
Jun 25, 1966·Nature·R Howe, R G Shanks
Sep 1, 1958·British Journal of Pharmacology and Chemotherapy·E M VAUGHAN WILLIAMS
Dec 1, 1961·British Journal of Pharmacology and Chemotherapy·E M WILLIAMS, L SZEKERES
May 16, 1964·Lancet·J W BLACKA C DORNHORST
Feb 1, 1965·The Journal of Pharmacology and Experimental Therapeutics·P SOMANI, B K LUM
Apr 1, 1965·British Journal of Pharmacology and Chemotherapy·A MORALES AGUILERA, E M VAUGHANWILLIAMS
Mar 1, 1962·The Journal of Physiology·L Szekeres, E M Williams

❮ Previous
Next ❯


Jan 1, 1990·European Journal of Clinical Pharmacology·K Endresen, J P Amlie
Mar 1, 1980·Naunyn-Schmiedeberg's Archives of Pharmacology·A J SzentmiklósiL Szekeres
Jan 1, 1971·Naunyn-Schmiedebergs Archiv Für Pharmakologie·H BrunnerM Meier
Dec 1, 1975·Agents and Actions·J G Papp, B A Resch
Jul 1, 1971·European Journal of Pharmacology·B Spilker, S Shevde
Jul 1, 1971·European Journal of Pharmacology·J R BoissierS Larno
May 1, 1971·European Journal of Pharmacology·A LangsletI Oye
Nov 1, 1972·European Journal of Pharmacology·G J Kelliher, J Roberts
Dec 1, 1973·European Journal of Pharmacology·V KecskemètiJ Knoll
Nov 1, 1974·European Journal of Pharmacology·E J Mylecharane, C Raper
Apr 1, 1975·European Journal of Pharmacology·J F GiudicelliJ R Boissier
Nov 1, 1975·European Journal of Pharmacology·B N SinghR M Whitlock
Oct 31, 1980·European Journal of Pharmacology·G Pogátsa, M Németh
Aug 1, 1970·British Journal of Pharmacology·B N Singh, E M Vaughan Williams
Nov 1, 1970·British Journal of Pharmacology·A M Barrett, J Carter
Nov 1, 1972·British Journal of Pharmacology·G KelliherJ Roberts
Apr 1, 1975·British Journal of Pharmacology·A J HoodD F Weetman
Jan 1, 1972·Acta Pharmacologica Et Toxicologica·H Refsum, K Landmark
Jul 9, 1977·British Medical Journal·A E Raine, T G Pickering
Feb 23, 1972·Nature: New Biology·R A Burges, K J Blackburn
Oct 1, 1980·British Journal of Pharmacology·A E Raine, E M Vaughan Williams
Nov 1, 1970·The Journal of Pharmacy and Pharmacology·A M Barrett, B Nunn

❮ Previous
Next ❯

Related Concepts

Related Feeds


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.